This study suggested the potential of Tf-LioNs as a delivery platform and that of Tf-MeLioNs for ameliorating amyloid-related pathologies in AD and provides a foundation for the use of Tf-MeLioNs as a promising AD treatment strategy. This evidence concerns the gene TF and amyloidosis.